Economic Times
Eli Lilly is set to acquire Ajax Therapeutics for a substantial sum. This move aims to develop a new oral treatment for myelofibrosis, a rare blood cancer. Clinical data is anticipated in 2026. Lilly plans to quickly move the treatment into larger trials. The company seeks to offer another vital medicine to patients and doctors specializing in blood cancers.
Go to News Site